• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel therapeutically active compounds of the formula wherein R is a straight or branched alkyl group with 6-18 carbon atoms, R1 is hydrogen, chlorine, bromine or an alkyl group with 1-3 carbon atoms and R2 is chlorine, bromine or an alkyl group with 1-3 carbon atoms; or a physiologically acceptable salt or an optical isomer thereof, methods and intermediates for their preparation, pharmaceutical preparations containing them and methods for their therapeutical use.
    公开号:SU1342412A3
    申请号:SU833643500
    申请日:1983-09-08
    公开日:1987-09-30
    发明作者:Де Паулис Томас；Ингвар Рамсби Стен；Ове Огрен Свен
    申请人:Астра Лекемедель Актиеболаг (Фирма)；
    IPC主号:
    专利说明:

    1342412
    The invention relates to a process for the preparation of new chemical compounds of the pyrrolidine series, namely, derivatives of N- (1-ethylpyrrolidinyl--2) methyl j-6-methoxybenzamide of the general formula p.
    for 5 m
    -e pi mi
    R OC-Ri
    L
    DOS
    N
    R, R.
    where R is a normal or branched C —C, -alkyl; chlorine, bromine or ethyl; hydrogen, chlorine, bromine or ethyl,
    which have an antipsychotic effect and can be used in medicine,
    The purpose of the invention is to develop, on the basis of a well-known method, a method of obtaining new chemical compounds of the pyrrolidine series, which possess valuable pharmacological properties,
    The invention is illustrated by the following examples.
    Example 1 S - (-) - 2-Decanoyl-oxy-3,5-diethyl-N- (1-ethyl-2-pyrrolidinyl) methyl-6-methoxybenzamide (1a (-) - 3, 5 Diethyl-Y- ( 1-ethyl-2-pyrro lidinyl) methyl -2-hydroxy-6-methoxybenzamide hydrochloride (1.85 g, 0.005 mol) was dissolved in 10 ml of trifluoroacetic acid. The acid of decanoic acid was added. The reaction mixture was stirred for overnight, after which the solvent was evaporated. A saturated solution of potassium bicarbonate was added to the residue, and the product was extracted with ether. After drying (MgSO4) and evaporating, 2.1 g (86%) of decanoate ester was obtained as an oil. On-layer chromatography on silica gel: a solvent mixture and 3.5 M NHj in ethanol (19: 1) produced a new spot at Rf 0.56 compared to Rf 0.63 for the starting material. The mass spectrum of the ester had a molecular peak at m / e 488.
    Compounds I according to examples 2-10 were prepared analogously.
    Example 2. 5 - (-) - 3-bromo-2- -decanoyloxy-N- (1-methyl-2-pyrrolidinyl) methyl} -6-methoxybenzamide (16)

    Rf 0.28 compared to Rf 0.38 for the starting material in tOH-NH3 (80: 20: 1). Mass spectrum 5 m / e 510/512.
    Example 3. S - (-) - 5-6poMo-2-decanoyloxy-3-etid-LH (-ethyl-2-. Pyrrolidinyl) methyl-6-methoxybenzamide (IB),
    0 Example 4. 8 - (-) - 3,5-dichloro- (2-ethylhexanoyloxy) -H- (1-ethyl- - 2-pyrrolidinyl) methyl-6-methoxybenzamide (1 g).
    Rf 0.64 in CHjClj-ftOH (4: 1). 5 Rf 0.23 in i-Pr O-MeOH (1: 4). Mass spectrum m / e 472/474.
    Example 5. 3 - (-) - 5-chloro-2-decanoyloxy-3-ethyl-N- (1-ethyl-2- -pyrrolidinyl) methyl-6-methoxybenzo-0 MFA (1d).
    Rf 0.56 in CH ,, (4: 1). Rf 0.30 to 1-Pr20-MeOH (1: 4). Mass spectrum m / e 494/496.
    Example 6. 5 - (-) - 3,5-dichloro-25 -2-nonanoyloxy-K- (-ethyl-2-pyrrolidinyl) methyl-6-methoxybenzamide (1e).
    Rf 0.49 in (4: 1). Rf 0.13 in i-Pr O-MeOH (1: 4). Mass-30 spectrum m / e 486/488.
    Example 7. S - (-) - 2-Decanoyl-hydroxy-3,5-dibromo-N- (1-ethyl-2-pyrrolidinyl) methyl-6-methoxybenzamide (1g),
    35 Example 8. 3 - (-) - 3.5-1Dichloro-2-o (-ethylvaleroyloxy-K- (1-ethyl--2-pyrrolidinyl) methyl-6-methoxybenzamide (1h).
    Example 9. I - (-) - 2-Decanoyl-40 hydroxy-3,5-dichloro-K- (1-ethyl-2-pyrrolidinyl) methyl-6-methoxybenzamide (1i).
    Rf 0.50 in CHjCl-ftOH (1: 4). Rf 0.14 R i-Pr, 0-MeOH. (4: 1). Mass 45 range 500/502.
    Example 10. 3 - (-) - 3,5-dichloro-2- | Y, sU-diethylbutyroyloxy-NG (.1- ethyl-2-pyrrolidinyl) methyl-6-methoxybenzamide (1k).
     gQ Example P. 3 - (-) - 3,5-dichloro-2-palmitoyloxy-N- (1-ethyl-2-pyrrolidinyl) methyl-6-methoxybenzamide (1 l).
    The compound was prepared according to the general procedure described in Example I. After preparation, the ether is purified from unreacted phenol by flash chromatography on a silica column using
    eluent of 5% methanol in isopropyl ether. The Rf value of the palmitate ester is 0.36 compared with 0.13 for the starting material purified by thin layer chromatography with eluant 20% methanol in isopropyl ether. The ester is a waxy solid with a m.p. 34 -. The IR and NMR spectra correspond to the structure. Mass spectrum m / e584. Example 12. 5 - (-) - 3,5-dichloro-2-steroyl-N- (1-ethyl-2-pyrrolidinyl) methyl-6-methoxybenzamide
    (I).
    This compound was prepared in a manner similar to the method for preparing the compound prepared in Example 11. Rf 0.44 in the same solvent system. The compound is recrystallized from hexane and has m, pl. 45 - 4b with. Mass spectrum m / e 612.
    The antipsychotic action of compounds I was studied.
    Male rats (weight 275 - 325 g) were used for the tests. The test compound is dissolved in arachis oil and, at a dose of 45 µmol / kg, is administered in UH by intramuscular injection. Tests on the same rats were carried out through. 2 hours and 3 days 30 minutes before the introduction of amphetamine by intraperitoneal injection at a dose of 1.5 mg / kg, the animals were placed in a cage, each animal in one cage (the floor size of the cage was 40x25 cm, height 30 cm). After 20 min, the measurement of mobility was started using 32 photos of cells located under the cell for four periods of 10 min. Each group consisted of 8 animals. The number of movements during 40 min of observation was calculated compared to control animals, which were administered only peanut butter. From these results, the percent inhibition of amphetamine was calculated.
    Compound 1L Test:
    Time Percentage of inhibition,%
    2h88
    3 days 31
    The test results show that the test compound 1l shows
    VNIIPI Order 4864 Circulation 371 Subscription Manufacture-polygr. pr-tie, Uzhgorod, st. Project, 4
    There is no inhibitory effect for at least 3 days, while the effect of 3 - (-) - L-ethyl-2- 3-bromo--2,6-dimethoxybenzamidomethyl) pyrrolidine hydrochloride (II) disappears already after 16 h
    Compounds I have low toxicity. Thus, LDjp with intraperitoneal injection of compound 1a 530 µmol / kg, IB 320 µmol / kg, 1 g 450 µmol / kg, 1l 660 µmol / kg.
    Thus, compounds I have a higher antipsychotic effect than compounds II,
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining derivatives of 20 N- (1-ethylpyrrolidinyl-2) -methyl - -6-methoxybenzamide of the general formula
    go: g
    25
    where R is normal or branched, 7-alkyl; Rj is chlorine, bromine or ethyl; RJ is hydrogen, chlorine, bromine or,
    ethyl,
    characterized in that the compound of the general formula
    RoOH Q
    rVc-i H-cH -O
    CHIN
    OSSN
    where Rn and RJ have the indicated meanings,
    subjected to interaction with the acid chloride of the general formula
    ABOUT
    II
    RI-C-CI
    where R has the indicated meanings.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1342412A3|1987-09-30|Method of producing derivatives of n-/|-methyl/-6-methoxybenzamide
    US4169152A|1979-09-25|Isohexide and tetrahydrofuran ethers and their carbamates in method of bringing about relaxation of skeletal musculature
    GB2143528A|1985-02-13|Salts of 2-|-phenyl acetic acid
    BG64560B1|2005-07-29|Benzazepine derivatives, medicamentous forms containing them, and their application for the preparation of medicaments
    CH634836A5|1983-02-28|HYDROXYMETHYL-5 OXAZOLIDINONES-2, MEDICINAL PRODUCT AND METHOD OF PREPARATION.
    EP0678514A1|1995-10-25|3,5-Disubstituted tetrahydrofuran-2-ones
    US4757069A|1988-07-12|Pyridazodiazepine derivatives
    DE69533043T2|2005-04-07|ACRYLAMIDE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
    SU1342415A3|1987-09-30|Method of producing derivatives of pyridazine
    EP0496238A1|1992-07-29|Substituted benzoxazepines and benzothiazepines, process for their preparation and their use as medicaments
    US5506249A|1996-04-09|Isoxazoles
    US3979405A|1976-09-07|2-Oxazoline derivatives
    EP0116360A1|1984-08-22|1-Phenyl-2-aminocarbonyl indoles, their preparation and medicines containing them
    CH520680A|1972-03-31|Ergot derivs andrenolytics
    EP0266308B1|1991-07-24|Indolo-pyrazino-benzodiazepine derivatives
    EP0146838B1|1987-07-22|methanesulfonates as anticancer agents
    US4727174A|1988-02-23|methanesulfonates as anticancer agents
    US3737443A|1973-06-05|Omega-guanidino acid amide derivatives and manufacturing the same
    SU645572A3|1979-01-30|Method of obtaining oxazole derivatives
    EP0067094A1|1982-12-15|Heterocyclic derivatives of amidoximes, their preparation and therapeutic uses
    EP0338435A1|1989-10-25|3,4-Dihydroxypyrrolidin-2-one derivatives, process for their preparation, agents containing them and their use as well as the intermediates resulting from the preparation
    KR830000654B1|1983-03-25|Method for preparing tetrahydro-2H-benzo [c] pyrrole
    US5137908A|1992-08-11|4-azahexacyclododecane compounds
    US2871258A|1959-01-27|Branched chain diammonio esters
    RU2128651C1|1999-04-10|N-butylamide 2-anilino-6,7-dihydro-5h-pyrindine-3- carboxylic acid having anti-inflammatory activity
    同族专利:
    公开号 | 公开日
    KR900008316B1|1990-11-12|
    FI78905B|1989-06-30|
    EP0117384A1|1984-09-05|
    GR79666B|1984-10-31|
    AT39482T|1989-01-15|
    CS239943B2|1986-01-16|
    PL243670A1|1985-03-12|
    PH18900A|1985-10-30|
    MY8700304A|1987-12-31|
    RO86674B|1985-05-01|
    HK14589A|1989-02-24|
    GB8324080D0|1983-10-12|
    GB2126585B|1986-04-23|
    NO161853B|1989-06-26|
    IE55907B1|1991-02-14|
    NO161853C|1989-10-04|
    IE832094L|1984-03-09|
    ES8501748A1|1984-12-01|
    IL69682A|1987-12-31|
    FI78905C|1989-10-10|
    NZ205527A|1986-04-11|
    IL69682D0|1983-12-30|
    PT77310B|1986-05-19|
    KR840006204A|1984-11-22|
    DD211552A5|1984-07-18|
    HU189745B|1986-07-28|
    JPH0471066B2|1992-11-12|
    DE3378761D1|1989-02-02|
    NO833219L|1984-03-12|
    US4937260A|1990-06-26|
    PT77310A|1983-10-01|
    RO86674A|1985-04-17|
    DK403883D0|1983-09-06|
    CA1207776A|1986-07-15|
    ES525488A0|1984-12-01|
    GB2126585A|1984-03-28|
    CS636283A2|1985-05-15|
    CY1461A|1989-07-21|
    PL139342B1|1987-01-31|
    FI833206A|1984-03-10|
    DK157846C|1990-07-23|
    EP0117384B1|1988-12-28|
    JPS5967260A|1984-04-16|
    ZA836280B|1984-04-25|
    DK157846B|1990-02-26|
    FI833206A0|1983-09-07|
    SE8205135D0|1982-09-09|
    DK403883A|1984-03-10|
    BG37992A3|1985-09-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR4879M|1964-01-13|
    BE695272A|1967-03-09|1967-09-11|
    CH507938A|1968-08-01|1971-05-31|Ile De France|Process for the preparation of heterocyclic benzamides|
    US3914418A|1971-09-02|1975-10-21|Merck & Co Inc|Methods of controlling liver fluke infections|
    US3793030A|1971-09-02|1974-02-19|Ricoh Kk|Process for producing diazotype light-sensitive material|
    US3862139A|1972-06-23|1975-01-21|Delmar Chem|Heterocyclic benzamide compounds|
    IT1070992B|1973-12-21|1985-04-02|Italfarmaco Spa|PROCESS FOR THE PREPARATION OF I ETHYL 2 2 METHOXY 5 SULFAMOIL BENZAMIDOMETHY PYROLIDINE|
    SE412908B|1974-12-18|1980-03-24|Synthelabo|PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE 2-METOXIBENZAMIDES CONTAINING A PYRROLIDINE OR A PIPERIDE REMINDER|
    FR2294698B1|1974-12-18|1979-03-16|Synthelabo|
    US4029678A|1975-12-08|1977-06-14|Hoffmann-La Roche Inc.|Asymmetric synthesis|
    JPS5319447A|1976-08-07|1978-02-22|Igeta Seikou Kk|Manufacture of endless wire rope|
    NZ186175A|1977-01-27|1980-03-05|Shionogi & Co|Meta-sulphonamidobenzamide derivatives|
    FR2440946B2|1978-01-20|1981-07-17|Ile De France|
    SE411118B|1978-03-23|1979-12-03|Astra Laekemedel Ab|A PROCEDURE FOR THE PREPARATION OF 2,6-DIALCOXIBENSAMIDES WITH THERAPENTIC PROPERTIES|
    FR2438650B1|1978-10-11|1981-08-14|Ile De France|
    IT1141095B|1980-11-27|1986-10-01|Ravizza Spa|RESOLUTION PROCESS OF THE SULPYRID RACEMA|
    SE8101536L|1981-03-11|1982-09-12|Astra Laekemedel Ab|Benzamide derivative|
    JPH0331704A|1989-06-29|1991-02-12|Matsushita Electric Ind Co Ltd|Aligning device|SE8400478D0|1984-01-31|1984-01-31|Astra Laekemedel Ab|OXYSALICYLAMIDO DERIVATIVES|
    US5240957A|1984-01-31|1993-08-31|Astra Lakemedel Akteibolag|Oxysalicylamido derivatives|
    US4772459A|1986-09-09|1988-09-20|Erbamont, Inc.|Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein|
    US5186921A|1989-04-17|1993-02-16|Trustees Of The University Of Pennsylvania|Dopamine receptor ligands and image agents|
    US5122361A|1989-04-17|1992-06-16|Trustees Of The University Of Pennsylvania|Dopamine receptor ligands and imaging agents|
    US5911970A|1993-05-06|1999-06-15|Research Corporation Technologies, Inc.|Methods for cancer imaging and therapy using benzamine compounds|
    US5993777A|1993-05-06|1999-11-30|Research Corporation Technologies, Inc.|Benzamide compounds for cancer imaging and therapy|
    WO1994026314A1|1993-05-06|1994-11-24|John Christy S|Compounds for cancer imaging and therapy|
    US6517811B2|1993-05-06|2003-02-11|Research Corporation Technologies, Inc.|Compounds for cancer imaging and therapy|
    DK72693D0|1993-06-18|1993-06-18|Lundbeck & Co As H|COMPOUNDS|
    KR20080055111A|2006-12-14|2008-06-19|제일모직주식회사|Pigment dispersed composition for image sensor color filter and color filter using the same|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE8205135A|SE8205135D0|1982-09-09|1982-09-09|Benzamido-DERIVATIVES|
    [返回顶部]